Chemotherapy-free combination regimens
| Regimen . | Study phase . | Disease setting . | Number of patients . | ORR (CR) . | Undetectable MRD rate . | Survival . | Reference . |
|---|---|---|---|---|---|---|---|
| TA + anti-CD20 antibodies | |||||||
| Ibrutinib vs | 3 | R/R | 58 | 47% | Pending | Pending | 32 |
| Ibrutinib, ublituximab (GENUINE) | 59 | 80% (P < .001) | |||||
| Acalabrutinib, obinutuzumab | 1b/2 | TN | 19 | 95% (16%) | N/A | Med f/u 17.8 mo in TN, 21.2 mo in R/R | 72 |
| R/R | 26 | 92% (8%) | Med PFS NR | ||||
| Ibrutinib vs | 2 | R/R | 188 | 98% (21%) | BM 17.1% | Med f/u 25.2 mo vs 22.7 mo | 36 |
| Ibrutinib, rituximab | 100% (28%) | BM 4.9% | PFS 91.2% | ||||
| 90.4% (P = .788) | |||||||
| Venetoclax, obinutuzumab | 1b | TN | 32 | 100% (56.3%) | PB 100% | 1 y | 38 |
| BM 62.5% | PFS 100% | ||||||
| Venetoclax, rituximab vs | 3 | R/R | 194 | 92.3% | PB 84% | Med f/u 23.8 mo | 42 |
| BR (MURANO) | 195 | 72.3% | PB 23% | PFS NR vs 17 mo (HR 0.17, P < .001) | 73 | ||
| Novel-novel combinations | |||||||
| Ibrutinib, venetoclax (CLARITY) | 2 | R/R | 50 (25 completed 6 mo combo) | 100% (60%) | BM 28% | N/A | 44 |
| Ibrutinib, venetoclax (CAPTIVATE) | 2 | TN | 163 (14 completed 12 mo combo) | 100% (36%) | PB 93% (after 12 mo) | N/A | 48 |
| BM 86% (after 12 mo) | |||||||
| Triple combinations | |||||||
| Obinutuzumab, ibrutinib, venetoclax | 1b/2 | TN | 25 (24 completed 8 mo) | 100% (50%) | PB (58%) | N/A | 49 |
| BM (58%) | |||||||
| Regimen . | Study phase . | Disease setting . | Number of patients . | ORR (CR) . | Undetectable MRD rate . | Survival . | Reference . |
|---|---|---|---|---|---|---|---|
| TA + anti-CD20 antibodies | |||||||
| Ibrutinib vs | 3 | R/R | 58 | 47% | Pending | Pending | 32 |
| Ibrutinib, ublituximab (GENUINE) | 59 | 80% (P < .001) | |||||
| Acalabrutinib, obinutuzumab | 1b/2 | TN | 19 | 95% (16%) | N/A | Med f/u 17.8 mo in TN, 21.2 mo in R/R | 72 |
| R/R | 26 | 92% (8%) | Med PFS NR | ||||
| Ibrutinib vs | 2 | R/R | 188 | 98% (21%) | BM 17.1% | Med f/u 25.2 mo vs 22.7 mo | 36 |
| Ibrutinib, rituximab | 100% (28%) | BM 4.9% | PFS 91.2% | ||||
| 90.4% (P = .788) | |||||||
| Venetoclax, obinutuzumab | 1b | TN | 32 | 100% (56.3%) | PB 100% | 1 y | 38 |
| BM 62.5% | PFS 100% | ||||||
| Venetoclax, rituximab vs | 3 | R/R | 194 | 92.3% | PB 84% | Med f/u 23.8 mo | 42 |
| BR (MURANO) | 195 | 72.3% | PB 23% | PFS NR vs 17 mo (HR 0.17, P < .001) | 73 | ||
| Novel-novel combinations | |||||||
| Ibrutinib, venetoclax (CLARITY) | 2 | R/R | 50 (25 completed 6 mo combo) | 100% (60%) | BM 28% | N/A | 44 |
| Ibrutinib, venetoclax (CAPTIVATE) | 2 | TN | 163 (14 completed 12 mo combo) | 100% (36%) | PB 93% (after 12 mo) | N/A | 48 |
| BM 86% (after 12 mo) | |||||||
| Triple combinations | |||||||
| Obinutuzumab, ibrutinib, venetoclax | 1b/2 | TN | 25 (24 completed 8 mo) | 100% (50%) | PB (58%) | N/A | 49 |
| BM (58%) | |||||||
BM, bone marrow; combo, combination; f/u, follow-up; Med, median; MRD, minimal residual disease; NR, not reached; PB, peripheral blood.